Low Long-Term Risk of Breast Cancer Recurrence After Nipple-Sparing Mastectomy

Nipple-sparing mastectomy (NSM) – an increasingly popular option for women undergoing treatment for breast cancer – not only achieves good cosmetic outcomes, but also low long-term risk of recurrent breast cancer, reports a study in the October issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Ten years after NSM, the rate of recurrent breast cancer is only 3%, according to the new research, led by ASPS Member Surgeon Mihye Choi, MD, of the Hansjörg Wyss Department of Plastic Surgery, New York University Langone Health. The researchers write, “Nipple-sparing mastectomy remains a viable option in the appropriately indicated patient with regards to long-term cancer recurrence.”

Not just improved cosmetic outcomes – NSM provides good long-term cancer control

In the NSM technique, the surgeon preserves the nipple and surrounding tissues for use in immediate breast reconstruction. Compared to conventional mastectomy, NSM allows for a more natural-looking reconstruction, leading to higher patient satisfaction. However, there is little information about the long-term risk of recurrent breast cancer after NSM.

Dr. Choi and colleagues evaluated breast cancer outcomes in 120 patients undergoing NSM for breast cancer treatment. The analysis included a total of 126 therapeutic NSM procedures. The analysis excluded prophylactic (preventive) NSM procedures to reduce the risk of breast cancer in women at high genetic risk.

At a median follow-up of 10 years after NSM, the analysis showed low recurrent cancer risks: 3.33% per patient and 3.17% per reconstructed breast. Of the four patients with recurrent cancer, two had local recurrences (breast only) and two had cancer spread to other locations (locoregional recurrence).

Recurrence risk was higher for women who had cancer involving the lymph nodes. However, on analysis adjusting for other factors, there were no demographic, surgical or tumor-related variables that predicted the risk of recurrent breast cancer.

The researchers point out some key limitations of their findings – including selection bias related to the characteristics of patients likely to be considered good candidates for NSM. Most of the patients in the study had early-stage breast cancers: stage 1 in about 45% and stage 0 in 34%.

The finding of good long-term cancer control is especially important in light of the growing use of NSM and immediate reconstruction for women with breast cancer. “Patients with NSMs have had low locoregional recurrence rates in a retrospective review of patients with a median follow-up of 10-years,” Dr. Choi and colleagues conclude. They add: “Despite low rates of recurrence, close surveillance remains important to continually assess for long-term safety of NSM.”

Plastic and Reconstructive Surgery® is published by Wolters Kluwer.

Click here to read “Long-Term Cancer Recurrence Rates following Nipple-Sparing Mastectomy: A 10-Year Follow-Up Study”

Article: “Long-Term Cancer Recurrence Rates following Nipple-Sparing Mastectomy: A 10-Year Follow-Up Study” (doi: 10.1097/PRS.0000000000009495)

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions and services for the clinicians, nurses, accountants, lawyers and tax, finance, audit, risk, compliance and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit www.wolterskluwer.com, and follow us on Twitter, Facebook, LinkedIn and YouTube.

Published at Wed, 28 Sep 2022 22:00:00 +0000